Publikationen in Zusammenarbeit mit Forschern von Dana–Farber Cancer Institute (6)

2023

  1. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

    Cancers, Vol. 15, Núm. 2

  2. Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

    The New England journal of medicine, Vol. 389, Núm. 11, pp. 1009-1022

2022

  1. Corrigendum to “P-137: ITHACA, A Randomized Multicenter Phase 3 Study of Isatuximab in Combination With Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: Safety Run-in Preliminary Results” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S109- S110] (Clinical Lymphoma, Myeloma and Leukemia (2021) 21(S2) (S1–S189), (S2152265021X00122))

    Clinical Lymphoma, Myeloma and Leukemia

2021

  1. Pathogenetic and prognostic implications of increased mitochondrial content in multiple myeloma

    Cancers, Vol. 13, Núm. 13

2020

  1. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

    Blood, Vol. 136, Núm. 26, pp. 3033-3040

2019

  1. Dual PAK4-NAMPT inhibition impacts growth and survival, and increases sensitivity to DNA-damaging agents in Waldenstrom € macroglobulinemia

    Clinical Cancer Research, Vol. 25, Núm. 1, pp. 369-377